3.37
전일 마감가:
$3.36
열려 있는:
$3.36
하루 거래량:
870.89K
Relative Volume:
0.51
시가총액:
$280.01M
수익:
-
순이익/손실:
$-36.95M
주가수익비율:
-4.0119
EPS:
-0.84
순현금흐름:
$-33.46M
1주 성능:
-13.81%
1개월 성능:
-8.92%
6개월 성능:
+5.31%
1년 성능:
-14.90%
Larimar Therapeutics Inc Stock (LRMR) Company Profile
명칭
Larimar Therapeutics Inc
전화
844-511-9056
주소
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
LRMR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
LRMR
Larimar Therapeutics Inc
|
3.37 | 279.18M | 0 | -36.95M | -33.46M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-29 | 개시 | Truist | Buy |
| 2024-10-16 | 개시 | Oppenheimer | Outperform |
| 2024-10-03 | 개시 | Wedbush | Outperform |
| 2024-10-02 | 개시 | H.C. Wainwright | Buy |
| 2024-09-04 | 개시 | Robert W. Baird | Outperform |
| 2024-04-03 | 개시 | Leerink Partners | Outperform |
| 2023-11-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-10-19 | 개시 | Guggenheim | Buy |
| 2022-02-15 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-02-10 | 개시 | JMP Securities | Mkt Outperform |
| 2021-02-01 | 개시 | William Blair | Outperform |
모두보기
Larimar Therapeutics Inc 주식(LRMR)의 최신 뉴스
Leerink Partners assumes coverage on Larimar Therapeutics stock with Outperform rating - Investing.com Canada
Short Interest in Larimar Therapeutics, Inc. (NASDAQ:LRMR) Decreases By 19.2% - MarketBeat
Why Larimar Therapeutics Inc. stock could rally in 2025Quarterly Portfolio Summary & Safe Entry Trade Reports - moha.gov.vn
Comparing Altimmune (NASDAQ:ALT) & Larimar Therapeutics (NASDAQ:LRMR) - Defense World
Larimar heads to JPMorgan as rare disease program draws investor attention - MSN
Larimar Heads to JPMorgan as Rare Disease Program Draws Investor Attention - MyChesCo
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Should I hold or sell Larimar Therapeutics Inc. stock in 20252025 Sector Review & Smart Money Movement Tracker - Улправда
How buybacks impact Larimar Therapeutics Inc. stock value2025 Major Catalysts & Advanced Technical Analysis Signals - Улправда
Will Larimar Therapeutics Inc. (ZA71) stock see valuation expansionMarket Activity Summary & Advanced Technical Signal Analysis - Улправда
How institutional buying supports Larimar Therapeutics Inc. stockJuly 2025 Update & Reliable Intraday Trade Plans - Улправда
Is Larimar Therapeutics Inc. stock a contrarian buyInsider Buying & Daily Technical Stock Forecast Reports - Улправда
Moving Averages: Can Larimar Therapeutics Inc. stock rebound after recent weakness2025 Earnings Surprises & Accurate Technical Buy Alerts - Улправда
Market Fear: How Larimar Therapeutics Inc. (ZA71) stock correlates with oil marketsJuly 2025 Outlook & Precise Swing Trade Entry Alerts - Улправда
How Larimar Therapeutics Inc. (ZA71) stock correlates with oil marketsJuly 2025 Gainers & Free Expert Approved Momentum Trade Ideas - Улправда
Published on: 2025-12-20 00:54:00 - Улправда
Why Larimar Therapeutics Inc. stock appeals to analysts2025 Stock Rankings & Risk Controlled Stock Alerts - Bölüm Sonu Canavarı
US Market Wrap: Will Larimar Therapeutics Inc. (ZA71) stock see valuation expansionMarket Growth Report & Short-Term Trading Alerts - Улправда
Published on: 2025-12-19 13:18:47 - ulpravda.ru
Published on: 2025-12-19 05:26:13 - Улправда
Is Larimar Therapeutics Inc. (ZA71) stock a buy during volatile marketsPrice Action & Comprehensive Market Scan Insights - Улправда
Why Larimar Therapeutics Inc. stock remains on buy lists2025 Sector Review & Risk Managed Investment Strategies - Улправда
Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Why Larimar Therapeutics Inc. stock is recommended by analystsPortfolio Gains Summary & AI Based Buy/Sell Signal Reports - Улправда
Larimar Therapeutics exchanges common stock for preferred shares in agreement with Blue Owl - Investing.com Australia
Larimar Therapeutics exchanges common stock for preferred shares in agreement with Blue Owl By Investing.com - Investing.com South Africa
Larimar Therapeutics Executes Strategic Stock Exchange Agreement - TipRanks
Larimar Therapeutics Earnings Notes - Trefis
Get in on Larimar Therapeutics Inc’s (LRMR) buy-in window today! - setenews.com
Can Larimar Therapeutics Inc. stock sustain market leadership2025 Winners & Losers & Weekly Return Optimization Alerts - Newser
How geopolitical risks impact Larimar Therapeutics Inc. (ZA71) stockMarket Rally & AI Enhanced Execution Alerts - Newser
Top 3 Health Care Stocks That May Rocket Higher In December - Benzinga
How Larimar Therapeutics Inc. (ZA71) stock behaves in tightening cyclesAnalyst Upgrade & Proven Capital Preservation Methods - Newser
Will Larimar Therapeutics Inc. (ZA71) stock recover faster than industry2025 Big Picture & Free AI Powered Buy and Sell Recommendations - Newser
Will Larimar Therapeutics Inc. (ZA71) stock profit from automation wave2025 Trade Ideas & Weekly Watchlist for Hot Stocks - Newser
Top investors say Larimar Therapeutics Inc (LRMR) ticks everything they need - Setenews
Why Larimar Therapeutics Inc. (ZA71) stock stays undervaluedWeekly Trend Recap & Comprehensive Market Scan Insights - Newser
Bronstein, Gewirtz & Grossman, LLC Encourages Larimar Therapeutic - The National Law Review
Is Larimar Therapeutics Inc a good long term investmentStock Rotation Strategies & High Return Capital Strategies - earlytimes.in
Short Covering May Lift Piccadily Sugar Allied Industries Limited in Near TermPrice Channel Trading & Small Budget Trading Tips - earlytimes.in
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Will Larimar Therapeutics Inc. stock outperform value stocks2025 Market WrapUp & Weekly Top Gainers Trade List - moha.gov.vn
Published on: 2025-11-27 11:17:59 - moha.gov.vn
Published on: 2025-11-26 23:31:58 - moha.gov.vn
Are Smart Investors Making the Right Decision? Larimar Therapeutics Inc (LRMR) - setenews.com
Larimar Therapeutics Advances Phase 1 Study on Nomlabofusp for Friedreich’s Ataxia - MSN
Should You Track Oswal Yarns Limited as a LongTerm Growth PlayTechnical Analysis Insights & Learn to Trade with Real-Time Feedback - earlytimes.in
Is Larimar Therapeutics Inc. stock a smart buy before Fed meetingForecast Cut & Daily Profit Focused Screening - newser.com
Larimar Therapeutics Highlights Promising Friedreich’s Ataxia Data - MSN
Why Larimar Therapeutics Inc. (ZA71) stock stays on top picksMarket Growth Review & Risk Controlled Swing Alerts - newser.com
Larimar Therapeutics Inc (LRMR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):